About
Andrew Cheng, M.D., Ph.D., is the President, Chief Executive Officer, and a director of Akero Therapeutics, a biotech company focused on serious metabolic disease including NASH/MASH. Before joining Akero in September 2018, he spent nearly two decades at Gilead Sciences, most recently as Chief Medical Officer and Executive Vice President. Public filings and insider-tracking data show he also holds a meaningful personal equity stake in Akero and has served as a director at other biotech companies.
Areas of interest
biotechmetabolic diseaseNASH/MASHdrug developmentclinical developmentliver disease